Published: December 15, 2016

Introduction {#sec1}
============

Sarcomeres, the basic contractile units of striated muscles, specialize in force generation through cyclic interactions of myosin and actin filaments. This fundamental activity requires the correct positioning of hundreds of proteins assembled in an overall functional architecture that need to respond to mechanical force in a cooperative, orchestrated way, as well as providing key integration of regulatory signals. The Z-disc and M-band sarcomeric regions ([Figure 1](#fig1){ref-type="fig"}A), although not directly involved in the actomyosin complex, are hubs where multiple structural and regulatory proteins are linked ([@bib17]). In particular, the central M-band, where titin filaments entering from opposite half-sarcomeres overlap, has been proposed as a structural safeguard of sarcomere integrity during force-generation cycles ([@bib1]).

Myomesin is a 185 kDa modular protein that localizes exclusively at the M-band, where anti-parallel dimers cross link myosin filaments ([Figure 1](#fig1){ref-type="fig"}B). It is expressed in all muscle types and its knockdown by siRNA results in a general failure in M-band assembly and the formation of disordered sarcomeres ([@bib15]). Long interdomain α-helices at the protein\'s C-terminus have been suggested to act as strain absorbers enabling myomesin to buffer mechanical forces between molecules during muscle work ([@bib43], [@bib61]). In addition to a mechanical role, myomesin is also needed for the integration of obscurin and its smaller obscurin-like-1 homolog at the M-band ([@bib15]). Together with titin\'s C-terminus, a hotspot for disease-related mutations ([@bib8], [@bib44]), myomesin recruits obscurin and obscurin-like-1 N-termini at the myofibril periphery and core, respectively, establishing a ternary complex ([Figure 1](#fig1){ref-type="fig"}B).

Obscurin and obscurin-like-1 share a common immunoglobulin (Ig)-rich modular structure, which, in the case of obscurin, is more extended, featuring additional signaling and protein-binding domains absent in obscurin-like-1 ([@bib15]). The presence of a non-modular C-terminus able to interact with small ankyrin-1 isoform 5 and ankyrin-2 led to the suggestion that obscurin plays a role in establishing the sarcomere-sarcoplasmic reticulum connection ([@bib3], [@bib27]). The pathophysiological roles of these proteins are only beginning to emerge. Ablation of obscurin in mice results in changes in longitudinal sarcoplasmic reticulum architecture with alterations in several SR-associated proteins ([@bib30]) as well as marked sarcolemma fragility and reduced muscle exercise tolerance ([@bib47]), while its depletion in zebrafish leads to disturbances in the extracellular matrix organization during skeletal muscle development ([@bib46]). The founding member of the obscurin family of proteins is UNC-89 in *Caenorhabditis elegans* ([@bib4]). *unc-89* loss-of-function mutant worms display reduced locomotion, disorganized myofibrils, and lack M lines ([@bib54], [@bib57]). *unc-89* mutants show disorganization of myosin thick filaments by immunostaining ([@bib45], [@bib59]). *Drosophila* expresses a protein more similar to nematode UNC-89 than to vertebrate obscurin. In *Drosophila,* RNAi experiments indicate that obscurin is needed for the formation of normal symmetrical sarcomeres ([@bib65]). However, fundamental differences exist in the domain patterns and likely functions of the signaling domains in vertebrate, insect, and nematode obscurins/unc-89 members. All obscurin/UNC-89 members contain a constitutively expressed Rho-type GDP/GTP exchange factor domain (GEF) with a preceding Src-homology-3 (SH3) domain, which in insect and nematode obscurin/UNC-89 are situated at the N-terminal end of the proteins, while in vertebrate obscurin, the GEF domain is at the C-terminus. In addition, obscurin/UNC-89 isoforms can contain up to two serine/threonine kinase domains ([@bib26], [@bib55]). In insect and nematode obscurin, these are catalytically inactive pseudokinases that form scaffolds for the interactions with regulators of sarcomere assembly and/or maintenance ([@bib26]), while the two differentially spliced kinases in vertebrate obscurin contain all canonical residues required for catalysis ([@bib14]) and were reported to be catalytically active in vitro ([@bib23]). Analyzing the molecular interactions and signaling functions therefore requires dedicated approaches for each of these presumptive homologs. From a pathological viewpoint, obscurin polymorphisms has been linked to hypertrophic cardiomyopathy ([@bib2]) and dilated cardiomyopathy ([@bib33]), while mutations in obscurin-like-1 have been linked to the rare hereditary growth retardation 3-M syndrome ([@bib24]) with a role in the maintenance of cullin-7 levels ([@bib19]). Understanding obscurin/UNC-89 functions thus also bears relevance to understanding the impact of pathogenic variants in human.

To advance knowledge on M-band organization and function, we have previously established the molecular basis for titin:obscurin-like-1 ([@bib39]) and titin:obscurin ([@bib40]) connection at the M-band. Obscurin and obscurin-like-1 use their homologous N-terminal immunoglobulin-like (Ig) domains (O1 and OL1, respectively) to bind titin\'s most C-terminal Ig domain (M10) in a mutually exclusive manner and in a unique chevron-shaped anti-parallel Ig-Ig architecture ([@bib39], [@bib40], [@bib50]). Mechanically, the M-band titin:obscurin(-like-1) junction is labile, as in single-molecule force spectroscopy experiments both M10:O1 and M10:OL1 complexes yield at forces of around 30 pN ([@bib39]). An obvious missing piece in the M-band structural puzzle is the molecular architecture of the obscurin(-like-1):myomesin complex, a key elusive element to understand the global geometry and mechanical stability defining the M-band. Using a multidisciplinary approach encompassing structural techniques, in vivo cellular competition assays, and single-molecule force spectroscopy experiments, we investigated here the myomesin-dependent mechanism of obscurin(-like-1) integration at the M-band.

Results {#sec2}
=======

Human Obscurin/Obscurin-like-1:Myomesin Complex for Structural Analysis {#sec2.1}
-----------------------------------------------------------------------

Large muscle proteins are typically modular, featuring several Ig and fibronectin-type-III (Fn-III) domains interspersed by linkers of variable length and structural order. Yeast two-hybrid and biochemical analyses have mapped the obscurin/obscurin-like-1:myomesin interaction to the linker region (*L*) located between the fourth and fifth Fn-III domains of myomesin (My4 and My5, respectively) and the third Ig domain of either obscurin or obscurin-like-1 (O3 and OL3, respectively) ([Figure 1](#fig1){ref-type="fig"}B, inset) ([@bib15]). O3 and OL3 are highly homologous, sharing 47.2% sequence identity. To produce protein complexes for structural analysis, we initially attempted the expression of isolated domains in *Escherichia coli,* but failed to obtain soluble O3 or OL3. We therefore decided to pursue a co-expression approach and cloned either O3 or OL3 C-terminal to a GST tag in the first expression cassette of a bicistronic vector, where the myomesin region encompassing the fourth and fifth Fn-III domains (My4*L*My5) was cloned in the second expression cassette. This strategy readily produced soluble protein for both constructs and size-exclusion chromatography (SEC) analysis of GST-cleaved complexes is consistent with the formation of obscurin(-like-1):myomesin heterodimers with a 1:1 stoichiometry ([Figure S1](#mmc1){ref-type="supplementary-material"}). Using a matrix microseeding (MMS) approach ([@bib11]), we successfully crystallized the OL3:My4*L*My5 complex and solved its structure at the 3.1 Å resolution. X-ray data collection and refinement statistics are given in [Table 1](#tbl1){ref-type="table"}. The final model is characterized by excellent statistics and *R/R*~free~ (%) values of 21.6/25.9. While the myomesin My4 domain and its C-terminal linker *L* as well as obscurin-like-1 OL3 are well defined in the structure, the entire myomesin My5 domain is invisible in electron density maps. Proteolysis during crystallization does not appear to be the reason for this, as SDS-PAGE analysis of dissolved crystals shows both My4*L*My5 and OL3 components at the expected molecular weight ([Figure S2](#mmc1){ref-type="supplementary-material"}). Thus, we conclude that the lack of electron density for My5 is due to its positional disorder in the crystal. As My5 is not visible in the structure, we hereafter refer to the crystallographic complex as to OL3:My4*L*.

Overall Organization {#sec2.2}
--------------------

The OL3:My4*L* complex is present as a (OL3:My4*L*)~2~ dimer of heterodimers in the crystal ([Figure 2](#fig2){ref-type="fig"}A). Individual OL3:My4*L* complexes display a bent dumbbell-shaped structure, in which the myomesin *L* linker extends away from the My4 domain integrating within the OL3 fold. Two OL3:My4*L* heterodimers then interlock around a non-crystallographic two-fold axis, giving rise to a dimeric assembly with overall dimensions of 105 Å × 48 Å × 26 Å. Large solvent channels running parallel to the molecular dyad axis are observed in the crystallographic packing ([Figure S3](#mmc1){ref-type="supplementary-material"}). These are compatible with the presence of positionally disordered My5 domains.

As the OL3:My4*L*My5 complex typically elutes from SEC as a monomeric unit during purification ([Figure S1](#mmc1){ref-type="supplementary-material"}), we analyzed its behavior at concentrations similar to that used for crystallization. In the accessible range of 3.0--8.2 mg/mL (0.082--0.225 mM), we observed the formation of complex dimers in a concentration-dependent manner with an approximately 30:70 dimer:monomer ratio at the highest protein concentration ([Figure 2](#fig2){ref-type="fig"}B). Thus, the oligomerization state observed in the crystal reflects that of a population in solution promoted by high protein concentration (∼15.9 mM in the crystal).

The OL3:My4*L* Heterodimer {#sec2.3}
--------------------------

Three distinct structural regions that we identify as My4, *L*~H~, and OL3~A~ contribute to the architecture of individual OL3:My4*L* heterodimers ([Figures 3](#fig3){ref-type="fig"}A and 3B). The My4 domain displays the typical Fn-III fold made of seven anti-parallel β-strands organized in two separate β-sheets (A-B-E and C-C′-F-G) arranged in a β sandwich. C′ is rather short, while G is broken in two (G′ and G″) and interacts with the beginning and end of the long F β-strand. C-terminal to My4, the *L*~H~ spacer region encompasses the first 11 amino acids of *L* and is formed by a 10.6-Å-long α-helix (Pro^607^-Lys^614^) followed by a short three amino acids peptide (Ser^615^-Pro^617^). *L*~H~ leads the C-terminal portion of *L,* an 18-amino-acid-long extended stretch divided into two β-strands (*L*~S′~ and *L*~S″~) that integrate within the OL3 Ig fold. Similar to the Fn-III architecture, the Ig fold is also organized into a β sandwich formed by two β-sheets (A′-G-F-C-C′ and *L*~S′~/*L*~S″~-B′/B″-E-D). As OL3 integrates structural elements of *L,* we refer to this portion of the complex as the augmented OL3 (OL3~A~) domain. The distinctively bent geometry of the heterodimer is dictated by the principal axes of My4 and OL3~A~ forming a ∼100° angle along the longest dimension of the complex. This, coupled with the 18.2-Å-long *L*~H~ region (Pro^607^-Pro^617^, Cα-Cα distance) that acts as a spacer between the domains, allows for the positioning of the second OL3:My4*L* complex within the tetrameric assembly ([Figure 2](#fig2){ref-type="fig"}A).

OL3~A~ is an example of fold complementation ([Figure 3](#fig3){ref-type="fig"}C), and the isolated OL3 domain is best described as an incomplete Ig of the intermediate-set (I-set) subfamily ([@bib20]). This type of Ig is often found in muscle proteins ([@bib36]) and consists of a total of nine strands arranged into two distinct β-sheets (A-B-E-D and A′-G-F-C-C′), exhibiting the characteristic discontinuous A/A′ strand distributed over both β-sheets ([Figure S4](#mmc1){ref-type="supplementary-material"}A). In OL3, the A β-strand that is hydrogen-bonded to B is missing and is replaced by myomesin *L*~S′~ (Ser^618^-Thr^622^), thus re-establishing a complete Ig architecture. A second myomesin strand (*L*~S″~, Ile^626^-Glu^630^) also hydrogen bonds to B″ at a position that is reminiscent of the A′ positioning found in a few deviant I-set Ig domains, identified as the I^∗^-set subtype ([@bib40]). Members of this subtype feature a relocation of their A′ strand, resulting in the formation of an A/A′-B-E-D β-sheet ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Thus, OL3~A~ is a complex *trans*-complemented hybrid I/I^∗^-set Ig fold.

Molecular Interfaces {#sec2.4}
--------------------

Two sets of molecular interfaces are present in the crystallographic structure. The first one is involved in the formation of the OL3:My4*L* heterodimer. An additional set of interactions enables its dimerization. As SEC analysis indicates that in solution the formation of the (OL3:My4*L*)~2~ assembly is promoted by high concentration of the complex ([Figure 2](#fig2){ref-type="fig"}B), this implies that homodimerization is hierarchically secondary to the establishment of the OL3:My4*L* interface.

As highlighted in the contact maps in [Figures 3](#fig3){ref-type="fig"}D and 3E, the OL3:My4*L* heterodimer is held together by Ig-fold complementation. A mixture of hydrogen bonds and hydrophobic interactions stabilizes the heterodimer ([Figure 3](#fig3){ref-type="fig"}F). One edge of the mixed *L*~S′~/*L*~S″~-B′/B″-E-D β-sheet is engendered by the anti-parallel pairing of *L*~S′~-B″ and *L*~S″~-B′ β-strands mediated by a total of 11 main-chain hydrogen bonds (in cyan in [Figure 3](#fig3){ref-type="fig"}F) connecting *L*~S′~/*L*~S″~ residues to B′/B″ residues. Side chains also stabilize the complex by hydrogen bonding (in pink in [Figure 3](#fig3){ref-type="fig"}F). They typically involve hydroxyl groups of Thr and Ser residues (myomesin S618, T628 and OL3 T328, S330) interacting with main-chain carbonyl oxygen atoms. A single salt bridge connects the carboxylate of myomesin E630 to the amine side chain of OL3 K305. A number of hydrophobic residues are buried upon complex formation. For example, myomesin I625 points its aliphatic side chain in a tight cavity lined by OL3 F265, W279, L304, Y317, C319, V332. Together with myomesin P620, T622, and V627, this residue buries more than 90% of its surface in the interaction, representing a critical determinant for binding. Overall, the OL3:My4*L* interface area is 1,046 Å^2^.

OL3:My4*L* homodimerization further stabilizes the assembly, resulting in the establishment of an interface area of 2,320 Å^2^ ([Figure S5](#mmc1){ref-type="supplementary-material"}). This is largely engendered by OL3^∗^:My4*L* (and symmetric OL3:My4*L*^∗^, where ^∗^ indicates that the domain belongs to the dimer partner), while My4*L*:My4*L*^∗^ and OL3:OL3^∗^ interactions are rather limited with interface areas of 122 Å^2^ and 278 Å^2^, respectively. PISA analysis ([@bib28]) indicates positive ΔG dissociation values of 14.5 kcal/mol and 12.75 kcal/mol for (OL3:My4*L*)~2~ and OL3:My4*L* stable assemblies, respectively.

Molecular Basis for Myomesin Isoform Specificity {#sec2.5}
------------------------------------------------

The myomesin gene family comprises three *MYOM* genes in humans ([@bib51]). *MYOM1* encodes the ubiquitously expressed myomesin protein, while *MYOM2* and *MYOM3* encode a fast-fiber isoform called M-protein or myomesin-2 and myomesin-3, a recently identified isoform of slow fibers, respectively. The interaction with obscurin/obscurin-like-1 is limited to myomesin, as neither M-protein nor myomesin-3 shows any appreciable binding ([@bib15]). Our X-ray structure explains the molecular basis for this specificity. Three myomesin residues mapping onto the *L* linker (T622, I625, and V627) display side chains that are complementary to the OL3 surface ([Figure 4](#fig4){ref-type="fig"}A). These are not conserved in either M-protein or myomesin-3 and occasionally exhibit rather dramatic amino acid substitutions. For example, myomesin T622 is replaced by a lysine in M-protein, while in myomesin-3 a more polar threonine takes the place of myomesin I625 ([Figure 3](#fig3){ref-type="fig"}E).

To validate the interaction between myomesin and obscurin/obscurin-like-1 in the context of the sarcomere, we generated a number of myomesin variants targeting the *L* linker and tested them for their ability to compete endogenous obscurin from the M-band. A quantitative analysis of these results is summarized in [Figure 4](#fig4){ref-type="fig"}B, while immunofluorescence images of representative experiments are shown in [Figures 4](#fig4){ref-type="fig"}C--4G and [S6](#mmc1){ref-type="supplementary-material"}. When overexpressed in neonatal rat cardiomyocytes (NRCs), GFP-My4*L*My5 targets the M-band, in addition to other diffuse subcellular localizations, displacing endogenous obscurin (first bar in [Figures 4](#fig4){ref-type="fig"}B and 4C). In the case of T622, its replacement with an isosteric valine (T622V) does not significantly alter the wild-type behavior (second bar in [Figures 5](#fig5){ref-type="fig"}B and [4](#fig4){ref-type="fig"}D). This is consistent with the lack of hydrogen bonding between the side chain of T622 and OL3 residues contributing to the small receptor cavity ([Figures 3](#fig3){ref-type="fig"}F and [4](#fig4){ref-type="fig"}A). However, when T622 is replaced by a lysine (T622K) as in M-protein (third bar in [Figures 4](#fig4){ref-type="fig"}B and 4E), or alternatively when I625 is replaced by a threonine like in myomesin-3 (fourth bar in [Figures 4](#fig4){ref-type="fig"}B and 4F), competition is essentially abrogated. A similar effect is mediated by the V627Y replacement also found in M-protein (fifth bar in [Figures 4](#fig4){ref-type="fig"}B and 4G). As expected, control substitutions targeting myomesin regions not involved in the interface have no effect on the ability to compete endogenous obscurin ([Figure S6](#mmc1){ref-type="supplementary-material"}).

The OL3:My4*L* Heterodimer Is a Flexible Structural Element {#sec2.6}
-----------------------------------------------------------

The bent dumbbell shape of OL3:My4*L* observed in the crystal is stabilized by its homodimeric assembly. As SEC analysis indicates that the complex is predominantly monomeric in solution, we explored whether this geometry is representative of the complex in solution using small-angle X-ray scattering (SAXS). The overall molecular parameters derived from scattering data on OL3:My4*L* and OL3:My4*L*My5 are shown in [Figure 5](#fig5){ref-type="fig"}A. A comparison of the experimental radius of gyration *R*~*g*~ for OL3:My4*L* (25.2 ± 2 Å) with that calculated from the structure (28.9 Å) indicates that in solution, the complex adopts a less extended conformation than in the crystal. Accordingly, the scattering pattern computed from the crystallographic model yielded a suboptimal fit (χ = 1.91) to the SAXS data ([Figure 5](#fig5){ref-type="fig"}B, upper curve, blue line), suggesting differences in the relative domain arrangement. To investigate the structure in solution, we considered the complex composed of three rigid bodies defined by the My4, *L*~H~, and OL3~A~ structural regions ([Figure 3](#fig3){ref-type="fig"}A). A good fit to the scattering curve was obtained with a model that is more compact than that seen in the crystal. We then used this structure as a starting template and, following energy minimization, generated \>30,000 additional models (a selection shown in [Figure 5](#fig5){ref-type="fig"}C) using the *tCONCOORD* ([@bib52]) algorithm, a computationally efficient method for sampling conformational transitions. Within this large pool, we found ∼500 models that provide an excellent fit (χ \< 1.0) to the experimental curves ([Figure 5](#fig5){ref-type="fig"}B, upper panel, red line). These models all display the *L*~H~ helix resting on the OL3~A~ domain, resulting in a less extended conformation compared with the dimer-stabilized crystal structure (a selection shown in [Figure 5](#fig5){ref-type="fig"}D). Additional SAXS data measured on OL3:My4*L*My5 reveal that inclusion of the My5 domain increases the *R*~*g*~ value to 31.0 ± 2 Å ([Figure 5](#fig5){ref-type="fig"}A). To model this complex, we started from the OL3:My4*L* solution model and again used *tCONCOORD* to sample the conformational space following addition of an additional Ig domain (My5). Several similar models provide an excellent fit (χ \< 1.0) to the scattering curve ([Figure 5](#fig5){ref-type="fig"}B, lower curve). We find that the OL3:My4*L* portion of the complex remains largely invariant, with My5 approximately orthogonal to OL3~A~ ([Figure 5](#fig5){ref-type="fig"}F).

The ability of OL3:My4*L* to transition from the solution conformation to that observed crystallographically suggests that the *L*~H~ helix might have a degree of flexibility. We explored this by solving the crystal structure of My4*L*~H~ (myomesin residues 510--618) in two different space groups (data collection and refinement statistics in [Table 1](#tbl1){ref-type="table"}). In space group *P*6~5~ (2.05 Å resolution), all four My4*L*~H~ independent molecules in the a.u. display clear electron density until residue A608, while residues E609-S618 (*L*~H~) cannot be modeled ([Figure S7](#mmc1){ref-type="supplementary-material"}A). The same applies for four of six My4*L*~H~ independent molecules in the alternative *P*2~1~ space group (2.80 Å resolution). However, in the latter crystal structure, crystal contacts stabilize the C-terminal region in the remaining two other My4*L*~H~ molecules. While in one molecule, *L*~H~ folds into an α-helix as in the My4*L*:OL3 complex ([Figure S7](#mmc1){ref-type="supplementary-material"}B), in the other molecule the C-terminus is in a more extended conformation ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Overall, SAXS and crystallographic analyses support a model in which interdomain freedom allows the transition (see [Movie S1](#mmc2){ref-type="supplementary-material"}) from a relatively compact solution conformation to an open one that can be stabilized by homodimerization.

Mechanical Stability of the Complex {#sec2.7}
-----------------------------------

It is enticing to speculate that the physical connection via swapped secondary structure elements might act as the molecular glue necessary for the mechanical stability of the obscurin(-like-1):myomesin assembly. To probe this, we employed single-molecule force spectroscopy using atomic force microscopy (AFM), and guided by the structure, we fused the C-terminus of the myomesin *L* linker to the N-terminus of OL3 by an unstructured 43 amino acids connector. This single-chain *L*-(connector)~43~-OL3 complex was then sandwiched between two ubiquitin (Ub) domains that serve as well-characterized handles ([@bib9]) ([Figure 6](#fig6){ref-type="fig"}A). The engineered polyprotein enables the unambiguous characterization of the forces required to break the molecular interactions that hold the complex together.

When stretched in our AFM setup at the constant velocity of 400 nm s^−1^ often employed in these types of studies ([@bib12], [@bib16], [@bib38]), the polyprotein unfolded displaying a saw-tooth pattern with peaks of alternating mechanical stability ([Figure 6](#fig6){ref-type="fig"}B). At the beginning of the trace, we identified two mechanical events with associated contour length increments of ΔL~1~ = 20.2 ± 1.2 nm (*n* = 66) and ΔL~2~ = 31.0 ± 0.9 nm (*n* = 68), respectively, followed by the unfolding of the two ubiquitin monomers (ΔL~Ub~ ∼24.5 nm), which serve as internal molecular calibration fingerprints ([Figure 5](#fig5){ref-type="fig"}B). Interestingly, the observed unfolding pattern does not follow the expected hierarchy of mechanical stability ([@bib31]). The first event occurs at a force value of 129.4 ± 27.0 pN (*n* = 66) while the second one only requires 86.6 ± 29.1 pN (*n* = 68) ([Figure 5](#fig5){ref-type="fig"}C). Both mechanical events are followed by the unfolding of the two Ub monomers, occurring at a higher force ∼200 pN ([@bib9]). Such unfolding scenario is hence reminiscent of a molecular mechanism whereby a mechanically labile domain is mechanically protected from the pulling force by a more resilient protein structure ([@bib37]).

The crystal structure shows that a stretch of 15 amino acids belonging to *L* lies within the OL3 domain. As the engineered protein connector is 43 residues long, the predicted length increase as a result of *L* detachment from OL3 is ΔL~1~=((15 + 43) residues × 0.36 nm/residue) = 20.88 nm. This value is in agreement with the experimental measurement (ΔL~1~ = 20.2 ± 1.2 nm, [Figure 5](#fig5){ref-type="fig"}D). The second unfolding event (ΔL~2~ = 31.0 ± 0.9 nm) corresponds to the unfolding and stretching of OL3 (89 amino acids). Thus, the single-molecule unfolding trajectories support an unfolding scenario whereby the first high-force event corresponds to the removal of the *L* linker from the OL3 domain, followed by the unfolding of OL3, occurring at a significantly lower force. To further confirm our molecular hypothesis, we constructed a second polyprotein in which the flexible connector length was lengthened to 64 residues. This new construct confirmed forces of 143 ± 29 pN (ΔL~1~ = 27.9 ± 1.5 nm) and 81 ± 22 pN (ΔL~2~ = 31.7 ± 1.2), for the detachment of the *L* latch and OL3 unfolding, respectively. As expected, while ΔL~2~ is invariant in the two polyproteins, the longer ΔL~1~ is fully consistent with the predicted extension of 28.4 nm ((15 + 64) residues × 0.36 nm/residue) for the longer connector ([Figure S8](#mmc1){ref-type="supplementary-material"}). Our single-molecule nanomechanical experiments thus unambiguously support a molecular organization in which the mechanically labile OL3 domain is protected from force by a more resilient architecture afforded by myomesin *L* complementation ([@bib37]).

Discussion {#sec3}
==========

The reason why muscle sarcomeres do not self-destruct during contraction lies in the intricate yet poorly understood cytoskeletal protein networks coordinated by titin at the Z-disk and M-band, which link actin and myosin filaments transversally and longitudinally ([@bib22]). The M-band network at the center of the myosin filaments is believed to play a key role as a mechanical safeguard during force-generating cycles and as a signaling hub ([@bib1]). Compared with the Z-disk, there is currently limited knowledge of this sarcomeric region. The reason for this is 2-fold. On the one hand, although the identity of some key M-band proteins is well established, new components are steadily emerging, suggesting that a much richer complement resides either stably or transiently at this region. For example, cardiomyopathy associated 5 protein (Cmya5 or myospryn) has been recently shown to bind to M-band titin and calpain-3 (Capn3) protease ([@bib49]). Mutations in Capn3 lead to limb girdle muscle dystrophy (LGDM) type 2A, and secondary Capn3 deficiency occurs in LGMD type 2J. Also, a novel leucine-rich protein named myomasp (\[myosin-interacting, M-band-associated stress-responsive protein\]/LRRC39) has been detected as an interactor of myosin heavy chain (MYH7), and knockdown of the myomasp/LRRC39 ortholog in zebrafish resulted in severely impaired heart function and cardiomyopathy in vivo ([@bib58]). On the other hand, even for known M-band protein components, their complexity is such that their detailed molecular organization is still largely unknown. Thus, advances in our understanding of M-band biology need to address its dynamic proteome, and the mechanical and architectural aspects underpinning its function.

In this work, we explored the myomesin-dependent anchoring of obscurin-like-1 to the M-band and found a mechanism that is new in the sarcomere context. The structure of the obscurin-like-1:myomesin complex reveals that the myomesin *L* linker between its fourth (My4) and fifth (My5) Fn-III domains integrates within the incomplete third Ig domain of obscurin-like-1 (OL3), resulting in a stable protein complex. The mechanism of fold complementation in-*trans* observed for the My4*L*:OL3 complex is somewhat reminiscent of that of subunit-subunit and chaperone-subunit interactions in bacterial pili assembled by the chaperone-usher pathway, whereby the binding partner inserts a β-strand into a partial Ig domain, thus restoring its fold ([@bib48]). In the case of OL3:My4*L,* this binding mode provides a surprisingly high mechanical stability to the complex (∼135 pN), a rupture force significantly higher than that required to unfold OL3 alone (∼85 pN) and quantitatively similar to that exhibited by the myomesin C-terminal dimer (∼137 pN) ([@bib5]) required for myosin crosslinking. The high force that the complex is able to withstand contrasts with the mechanical lability (∼30 pN) measured for the titin:obscurin/obscurin-like-1 complex between M10:OL1/O1 Ig domains ([@bib39]). Such mechanically weaker interaction reflects a completely different structural architecture, based on a parallel β-strand augmentation in an Ig:Ig chevron-shaped zipper module ([@bib39], [@bib40], [@bib50]). Interestingly, the low rupture force of the latter interaction is on the order of only about six myosin crossbridges, thus stable anchoring of obscurin-like-1 to the M-band appears to be dependent on its binding to myomesin rather than to titin. Given the high sequence similarity between OL3 and obscurin O3, particularly for the residues involved in the molecular interface with myomesin ([Figure 3](#fig3){ref-type="fig"}E), we suggest that the same holds true for obscurin anchoring and that the obscurin:myomesin complex recapitulates OL3:My4*L* in its binding mode. This closely mirrors the behavior of N-terminal Ig domains OL1 and O1 that interact with titin M10 in a mutually exclusive manner using a common interface. However, as for OL1 and O1, where minor, yet significant, structural differences suggest different specificities for putative additional partners ([@bib40]), we cannot exclude a similar unanticipated behavior for OL3/O3 as well. Interestingly, both OL3 and O3 are insoluble in bacteria when expressed in isolation, while co-expression in the presence of the myomesin *L* region results in biochemically well-behaved complexes. This suggests a chaperone effect by myomesin, effectively enabling the correct folding of the unconventional augmented O(L)3~A~ Ig domain. Crucially, removal of the *L* linker from OL3~A~ results in a semi-folded state with a significantly decreased mechanical stability, requiring only ∼85 pN to unfold.

A mechanism of β-strand complementation between linkers or non-structured regions with incomplete Ig domains has also been observed, both in-*cis* and in-*trans*, in Ig domains of the actin crosslinking protein filamin. Filamin A can interact with the cytoplasmic tail of integrin 3 via its Ig-like domain 21 (FLNa21), but FLNa21 can also bind to the linker between FLNa20 and 21 in an intramolecular complex that competes with integrin. Intriguingly, the removal of the *trans*-complemented β-strand from FLNa21 unmasks the binding site for integrin, which, when bound to filamin, engages integrin an inactive state ([@bib21], [@bib32]). This specific interaction can be opened by mechanical stretch and triggers integrin binding, filamin\'s partner in mechanosensing ([@bib10], [@bib53]). The intermolecular domain *trans*-complementation we observe here for the obscurin(-like-1):myomesin complex might therefore also play a role in mechanosensing, by freeing the O3/OL3 domain for binding to an alternative ligand. As obscurin-like-1 has been linked to ubiquitin-mediated turnover, such a mechanosensing pathway around the obscurin/obscurin-like-1:myomesin complex might feed into the turnover of sarcomere-associated structures ([@bib30]). Myomesin crosslinks myosin filaments and therefore must be exposed at least to some of the shear forces developing transversally to the myosin filament axis, but the extent to which myomesin is directly exposed to mechanical force in vivo remains unknown, not least because the exact orientation with respect to the filament axis can currently be only indirectly inferred, and the geometry of force transmission is therefore unclear. It is also yet unclear in which directionality mechanical forces act on the titin-obscurin, which might be relevant based on recent molecular dynamics simulations ([@bib7]). However, it is reasonable to speculate that the extremely stable anchoring of obscurin(-like-1) to myomesin is not only structurally important, but has evolved also as functionally relevant for nanomechanical necessity, supporting the notion that the M-band is a key strain sensor in muscle sarcomeres ([@bib1], [@bib43], [@bib61]).

The *MYOM* gene family codes for three proteins sharing a similar Ig/Fn-III-rich domain organization. Our OL3:My4*L* structure offers a clear structural basis for the specificity of obscurin(-like-1) binding to the myomesin-1 isoform that was validated by competition assays in the relevant cellular context of NRCs. Interestingly, the OL3:My4*L* complex also reveals interdomain flexibility and the ability to dimerize. The dimeric arrangement observed in the crystal and in solution at high protein concentration opens the possibility that this geometry might reflect the local obscurin(-like-1):myomesin organization in the crowded environment of the sarcomere. The M4/M4′ lines typical of striated muscles define a hexagonal arrangement of myosin filaments in the super-lattices of most vertebrates. Antibody mapping experiments suggested that the N-terminal region of myomesin runs roughly perpendicular to the myosin filament, since My1 and the *L* loop are only 7 nm apart from the M1 line ([@bib35]). Thus, it is conceivable that myomesin molecules emanating from neighboring myosin filaments of the hexagonal lattice cross over at the level of the *L* linker as seen in the OL3:My4*L* dimer ([Figure 7](#fig7){ref-type="fig"}). The intrinsic flexibility of the complex monomer coupled with the presence of the helical spacer at the *L* N-terminus appears perfectly poised for this. This suggestion is compatible with previous M-band models ([@bib29]) but adds a novel geometric constraint. In summary, our work provides a necessary structural and biomechanical reference to establish the geometrical context and mechanical hierarchies in M-band assembly, which will need to be reconciled with more highly resolved in situ information of this protein network and its response to mechanical stress.

Experimental Procedures {#sec4}
=======================

Detailed methods used for cloning, protein expression, and protein purification are given in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Crystallization {#sec4.1}
---------------

An initial vapor-diffusion sparse matrix screening performed using the sitting-drop setup with the aid of Mosquito crystallization robot (TTP LabTech) produced hundreds of OL3:My4*L*My5 microcrystals in the presence of 1.1 M ammonium tartrate (pH 7.0) and a 1:2 protein:reservoir ratio. The protein concentration used in the screen was 4.0 mg/mL in storage buffer (20 mM HEPES, 150 mM NaCl, 1 mM DTT \[pH 7.5\]). A standard pH-precipitant grid optimization allowed us to obtain fewer marginally larger crystals in the presence of 0.8 M ammonium tartrate, 0.1 M sodium acetate (pH 5.5) using a 1:1 protein:reservoir ratio. These crystals, however, proved unsuitable for diffraction experiments. To further improve crystal quality, we employed the random MMS screening approach ([@bib11]). Crystals obtained in the optimization step were harvested and stored in a solution containing 0.9 M ammonium tartrate, 0.1 M sodium acetate (pH 5.5) (hit stock). A new sparse matrix screening was performed using various commercial screens using a hit stock:protein:reservoir ratio of 1:2:1. Few OL3:My4*L*My5 single crystals were finally obtained in the presence of 20% PEG8000, 0.1 M Tris-HCl (pH 8.5), 0.2 M MgCl~2~ using the protein complex at 3.0 mg/mL. Crystallization of My4*L*~H~ is described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

X-Ray Data Collection and Structure Determination {#sec4.2}
-------------------------------------------------

Crystals were cryo-protected by soaking them in their reservoir solution supplemented with 20% glycerol. For OL3:My4*L*My5 a 3.1 Å resolution dataset was collected in space group *C*2 while My4*L*~H~ crystallized in the alternative space groups *P*6~5~ and *P*2, yielding diffraction data at 2.05 Å and 2.8 Å resolution, respectively. All datasets were collected at Diamond Light Source synchrotron facility (Didcot, Oxfordshire, UK) and processed with the *xia*2 expert system ([@bib60]) using *XDS* ([@bib25]) and *AIMLESS* ([@bib13]) packages. All X-ray structures were solved by the molecular replacement method with the package *MOLREP* ([@bib56]) and refined using the programs *REFMAC*5 ([@bib34]) and *BUSTER* ([@bib6]). A summary of data collection and refinement statistics is shown in [Table 1](#tbl1){ref-type="table"}. Further details on the crystallographic methods are available in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cellular Competition Assays in NRCs and Ratiometric Analysis {#sec4.3}
------------------------------------------------------------

NRC isolation, culture, transfection, and staining were performed essentially as described previously ([@bib39]). Briefly, NRCs were transfected with GFP-tagged transiently expressing constructs (pEGFPC2-, Clontech Laboratories) using Escort III (Sigma-Aldrich). After 48 hr culture to promote protein expression, cells were fixed with 4% paraformaldehyde/PBS, permeabilized with 0.1% Triton X-100/PBS, and then stained with the appropriate antibodies. The antibodies used for the current work were as follows: MyB4, a mouse monoclonal antibody to the myomesin domain My12 ([@bib18]); and Ob5859, a rabbit polyclonal antibody to two consecutive Ig domains in obscurin, Ob58 and Ob59 ([@bib14], [@bib62]). All fluorescent-conjugated secondary antibodies were purchased from Jackson ImmunoResearch. All images for ratiometry analysis were collected on a Zeiss LSM510 confocal microscope as described previously ([@bib15]). Image analysis was carried out as described in our previous work ([@bib40]). Further details are available in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Small-Angle X-Ray Scattering {#sec4.4}
----------------------------

Synchrotron SAXS data for OL3:My4*L* and OL3:My4*L*My5 were collected at the BM29 BioSAXS beamline (ESRF, Grenoble) using a Pilatus 1M detector (Dectris) ([@bib64]). All samples were measured at four concentrations (0.5--4.5 mg/mL in 20 mM HEPES \[pH 7.5\], 500 mM NaCl, 1 mM DTT buffer) in the range of momentum transfer 0.005 \< *s* \< 0.608 Å^−1^ (*s* = 4πsinθ/λ, where the wavelength λ is 0.9919 Å and 2θ is the scattering angle). All experiments were performed at 18°C using a sample volume of 30 μL loaded into the flowing measurement cell. Individual frames were processed automatically and independently within the *EDNA* framework ([@bib63]). Merging of separate concentrations and further analysis steps were performed using a combination of tools from the *ATSAS* package ([@bib41]). Initial rigid body modeling of the complex was done with *CORAL* ([@bib41]) and domain dynamics of the protein complexes was further explored by generating conformational ensembles using the *tCONCOORD* ([@bib52]) method. Further details are available in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Single-Molecule Mechanical Experiments by Atomic Force Microscopy {#sec4.5}
-----------------------------------------------------------------

cDNA was commercially synthesized (Genscript), which allowed the expression of a polyprotein in which the myomesin linker *L* and the obscurin-like-1 OL3 domain are connected by a flexible 43-amino-acid-long connector sandwiched between two ubiquitin (Ub) domains (Ub-*L*-connector-OL3-Ub). The synthetic gene was inserted into a pQE80L vector (QIAGEN) using standard molecular biology techniques. A PCR-based approach also allowed the extension of the connector length to 64 amino acids. Single proteins were picked up from the surface and pulled at a constant velocity of 400 nm s^−1^ ([@bib12], [@bib16], [@bib38]). Further details are available in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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![Schematic of the M-Band Network\
(A) Principal sarcomere regions are marked by the letters Z, I, A, and M.\
(B) Modular myomesin, titin, and obscurin/obscurin-like-1 proteins form an intricate M-band network with C-terminal myomesin dimers crosslinking myosin filaments. The inset highlights the interaction between myomesin and obscurin/obscurin-like-1, which has been mapped to linker sequence (*L*) located between the myomesin fibronectin (Fn-III) domains My4 and My5 and the third immunoglobulin (Ig) domain of obscurin/obscurin-like-1 (O3/OL3, respectively) ([@bib15]).](gr1){#fig1}

![The (OL3:My4*L*)~2~ Complex Dimer\
(A) In the crystal, two OL3:My4*L* heterodimers are arranged around a non-crystallographic two-fold axis (vertical in this view) forming a W-shaped (OL3:My4*L*)~2~ dimeric assembly. My4*L* and OL3 are in slate blue and green, respectively, with one heterodimer shown as a solid surface and the other in cartoon mode with a transparent surface. The dotted line at the C-terminus of *L* indicates the flexible region leading to My5 not visible in the structure.\
(B) Superdex S75 10/300 SEC traces for the OL3:My4*L*My5 complex injected in the column at 3 mg/mL (thin continuous line) and 8.2 mg/mL (thick continuous line). The OL3:My4*L*My5 complex forms a mixture of monomers and dimers in a concentration-dependent manner. The elution profile of calibration markers is shown with a gray broken line. Molecular weights are indicated.](gr2){#fig2}

![OL3:My4*L* Heterodimer\
(A and B) Cartoon representation of the OL3:My4*L* heterodimer. The view in (B) is rotated by 90° around the *x* axis compared with (A). My4*L* and OL3 are shown in slate blue and green, respectively. In (A), the three main regions contributing to the complex are highlighted: the My4 Fn-III domain, its C-terminal helical spacer *L*~H~, and the OL3~A~ (A for augmented) domain in which the Ig OL3 domain is stabilized by myomesin fold complementation in-*trans*.\
(C) Topology diagram of the complex.\
(D and E) Sequence alignment of the linker region for the different myomesin isoforms (D) and of the OL3 and O3 domains (E). Identical amino acids are highlighted. Colored circles above the secondary structure cartoons show residues of one domain contacting the other as indicated in the inset. Their radius is proportional to the buried area. The letter codes H and S indicate residues involved hydrogen bonds and salt bridges, respectively.\
(F) Enlarged stick representation of the boxed region in the top left-hand corner (view rotated approximately 90° around the *x* axis compared with B) highlighting important myomesin:obscurin-like-1 interactions. Nitrogen, oxygen, and sulfur atoms are shown in blue, red, and yellow, respectively. Hydrogen bonds involving main-chain atoms only are shown as dotted cyan lines. H bonds and salt bridges involving side chains are indicated by dotted magenta lines.](gr3){#fig3}

![Cellular Validation and Myomesin Isoform Specificity\
(A) Close up of the OL3:My4*L* interface. OL3 is shown as surface representation and colored according to its electrostatic potential. The myomesin *L* linker interacting with OL3 is shown as stick representation.\
(B) Quantification of endogenous obscurin displaced in neonatal rat cardiomyocytes expressing GFP-fused wild-type My4*L*My5 (*n* = 11) and its T622V (*n* = 10), T622K (*n* = 9), I625T (*n* = 10), V627Y (*n* = 13) variants. Amino acid replacements in the *L* linker inspired by myomesin-2 (T622K and V627Y) and myomesin-3 (I625T) sequences abrogate competition. Error bars are SEM values. ^∗∗∗^p ≤ 0.001.\
(C) Example of the competitive effect of overexpressed GFP-fused My4*L*My5 (WT) on endogenous obscurin in NRCs. The separate channels for endogenous myomesin, GFP, endogenous obscurin, as well as the combined and ratiometric images with overlaid GFP mask for the outline of the transfected cell are shown. The false-color scale range indicator shows an increased obscurin/myomesin ratio. The scale bar represents 10 μm.\
(D--G) Similar to (C) for overexpressed GFP-fused My4*L*My5 T622V (D), T622K (E), I625T (F), and V627Y (G). The scale bar represents 10 μm.](gr4){#fig4}

![Small-Angle X-Ray Scattering Analysis of the Myomesin:Obscurin-Like-1 Complex\
(A) Molecular parameters calculated from SAXS data. MM, *R*~*g*~, *D*~*max*~ are the molecular mass, radius of gyration, and maximum size, respectively. The superscript exp denotes experimental values while xt, *ai*, and tC refer to crystal, ab initio, and *tCONCOORD* fitted models, respectively. MM^calc^ is the theoretical MM computed from the protein sequence. χ is the discrepancy between experimental data and those computed from models.\
(B) Experimental scattering intensities for OL3:My4*L* (upper curve) and OL3:My4*L*My5 (lower curve) are displayed as dots with error bars. Curves computed from the crystallographic model and the best tC models are shown as solid blue and red lines, respectively, while the curve computed from the ab initio models is shown as a dotted green line.\
(C) Cartoon-tube representation of a selection of 20 OL3:My4*L tCONCOORD* models (out of \>30,000) aligned with respect to their My4 domain. My4*L* is in slate blue and OL3 is in green.\
(D) Cartoon-tube representation of the ten OL3:My4*L tCONCOORD* models providing the best fit to the SAXS data (0.78 \< χ \< 0.81).\
(E and F) OL3:My4*L* SAXS molecular envelope calculated from the ab initio model with a representative *tCONCOORD* model in two orthogonal orientations; (F) like (E) for OL3:My4*L*My5.](gr5){#fig5}

![Fold Complementation by the Myomesin *L* Linker Protects the Mechanically Labile OL3 Domain\
(A) Schematics of the ubiquitin-*L*-(connector)-OL3-ubiquitin polyprotein used in the single-molecule mechanical experiment. The 43 amino acid flexible connector covalently joining *L* to OL3 is depicted as a dashed line. The color code for *L* and OL3 is as in previous images. Ubiquitin (Ub) molecules bracketing the complex are in gray while the gold substrate and the atomic force microscopy (AFM) cantilever tip are shown in yellow and black, respectively.\
(B) Typical force-extension trace for the ubiquitin-*L*-(connector)~43~-OL3-ubiquitin polyprotein exhibiting a saw-tooth pattern of unfolding events that does not follow a hierarchy in the mechanical stability: the first unfolding event occurs at higher forces than the second unfolding event. The unfolding of the ubiquitin modules, occurring at forces of ∼200 pN and characterized by an increment of contour length of Δ*L*~Ub~ ∼24.5 nm, ensures the single-molecule nature of the experiment.\
(C) Histogram of unfolding forces. The first two events can be readily identified in light of their different mechanical stability and increment in contour length. While the first peak occurs at forces as high as 129.4 ± 27.0 pN (*n* = 66), the second peak unfolds at the markedly lower force of 86.6 ± 29.1 pN (*n* = 68).\
(D) Histogram of contour length increase: Δ*L*~1~ = 20.2 ± 1.2 nm (*n* = 66) and Δ*L*~2~ = 31.0 ± 0.9 nm (*n* = 68). In (C) and (D), colored curves are Gaussian fits.](gr6){#fig6}

![Possible Model for the Organization of the Titin:Obscurin(-like-1):Myomesin Ternary Complex at the M-Band\
Experimental complexes are shown as surface representation: OL3:My4*L* dimer (this work), M10:OL1 ([@bib39], [@bib40], [@bib50]), My9-M13 ([@bib42], [@bib43]).](gr7){#fig7}

###### 

X-Ray Data Collection and Refinement Statistics

  ------------------------------------------------------- ------------------------------- ------------------------------- -------------------------------
  **Data Collection**                                                                                                     
                                                                                                                          
  Dataset                                                 OL3:My4*L*                      My4*L*~H~ (1)                   My4*L*~H~ (2)
  Beamline                                                I04 (DLS)                       I04 (DLS)                       I04-1 (DLS)
  Wavelength (Å)                                          0.9778                          0.97949                         0.92819
  Resolution range[a](#tblfn1){ref-type="table-fn"} (Å)   67.19--3.10 (3.18--3.10)        84.36--2.05 (2.11--2.05)        39.21--2.80 (2.87--2.80)
  Space group                                             *C*2                            *P*6~5~                         *P*2~1~
  Cell dimensions                                                                                                         
  (a, b, c) (Å)                                           91.18, 134.38, 68.39            97.41, 97.41, 106.15            43.53, 156.84, 48.26
  (α, β, γ) (°)                                           90, 92.50, 90                   90, 90, 120                     90, 94.38, 90
  Unique reflections[a](#tblfn1){ref-type="table-fn"}     14,811 (1,064)                  35,371 (2,587)                  15,138 (1,048)
  Overall redundancy[a](#tblfn1){ref-type="table-fn"}     4.5 (4.5)                       20.0 (20.0)                     3.1 (3.1)
  Completeness[a](#tblfn1){ref-type="table-fn"} (%)       99.1 (98.2)                     99.9 (98.7)                     95.3 (89.8)
  *R*~merge~[a](#tblfn1){ref-type="table-fn"} (%)         9.8 (69.8)                      13.4 (242.1)                    9.0 (31.4)
  *R*~p.i.m.~ (I)[a](#tblfn1){ref-type="table-fn"} (%)    6.2 (44.3)                      3.6 (56.7)                      8.1 (24.5)
  〈I/σ(I)〉[a](#tblfn1){ref-type="table-fn"}             12.7 (1.8)                      13.4 (1.6)                      10.8 (3.1)
                                                                                                                          
  **Refinement**                                                                                                          
                                                                                                                          
  PDB code                                                [5FM5](pdb:5FM5){#intref0030}   [5FM8](pdb:5FM8){#intref0035}   [5FM4](pdb:5FM4){#intref0040}
  *R*~factor~ (%)/*R*~free~ (%)                           21.6/25.9                       19.2/21.7                       26.1/28.7
  Twin/twin fraction                                      no                              k,h,−l/0.67                     no
  No. of non-H atoms                                                                                                      
  Protein                                                 3,482                           3,142                           4,726
  Water                                                   84                              140                             37
  Average *B* value (Å^2^)                                85.5                            50.1                            35.2
  Root-mean-square bond lengths (Å)                       0.009                           0.013                           0.005
  Root-mean-square bond angles (°)                        1.46                            1.72                            1.07
  ------------------------------------------------------- ------------------------------- ------------------------------- -------------------------------

Numbers in parentheses refer to the highest resolution bin.

[^1]: Present address: Single Particles, Clusters, and Biomolecules and Serial Femtosecond Crystallography (SPB/SFX), European XFEL GmbH, Holzkoppel 4, 22869 Schenefeld, Germany

[^2]: Lead Contact
